Navigation Links
MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
Date:8/23/2007

New Facility Allows MedImmune to Meet Increasing Demands for Clinical Trial

Materials from Company's Expanding and Advancing Pipeline

GAITHERSBURG, Md., Aug. 23 /PRNewswire-FirstCall/ -- MedImmune today unveiled a new, state-of-the-art pilot lab facility located on the same Gaithersburg site as its headquarters. With its cutting-edge equipment and process automation systems, the facility will support MedImmune's expanding clinical product pipeline by providing additional capacity and flexibility.

At a ribbon-cutting event for the pilot lab held today at MedImmune, David M. Mott, president and chief executive officer, stated: "Completing this new facility is an important milestone, signaling our continued growth and success as a world-class biopharmaceuticals company. The opening of this facility, alongside the expansion work underway on our new biologics facility in Frederick, Maryland, reaffirms our leadership role within the state's biotechnology industry and demonstrates our ongoing commitment to the region."

The new pilot lab's 5,000 liters of bioreactor capacity will result in a four-fold increase in production capabilities. With the expanded facility, MedImmune will be able to produce clinical trial materials at a greater scale and in greater quantities, aiding in the testing of potential new products.

"This substantial increase in MedImmune's clinical production infrastructure supports our robust pipeline of product candidates," said Gail Folena-Wasserman, Ph.D., senior vice president, development. "The pilot lab facility is intended to meet our current and future needs, not just through its increased capacity but also through design flexibility, which efficiently allows us to produce multiple clinical products in the same space. We can drive efficiency and meet rigorous quality standards by incorporating the latest technology, including an advanced process control system."

In December 2006, the City of Gaithersburg approved the new pilot lab facility for occupancy. The facility will become the primary site for production of MedImmune's therapeutic proteins, replacing the existing Gaithersburg Manufacturing Development Facility (GMDF) where those clinical trial materials are currently produced. Material production is expected to begin in 2008, following the final stages of equipment validation. MedImmune plans to upgrade GMDF in the near future to provide added support for its development needs.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Why Files celebrates decade of science exploration
2. Young Professionals of Milwaukee Celebrates Its Third Birthday, Looks To The Future
3. Internet Scout celebrates 10 years on web, eyes new project launch
4. Farm Aid celebrates 20-year journey, heads back to Illinois roots
5. UW Office of Corporate Relations Celebrates Early Accomplishments
6. Its All Fun And Games in Madison - Raven Software Celebrates 15 Anniversary
7. Merge files financial reports by market opening
8. RFID pilot project aims to improve blood banks
9. Pilot fund brings capital to Eau Claire area innovations
10. National $100m pilot program to begin mapping cancer genome
11. Milwaukee health provider network pilots software plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):